The consensus price target hints at a 95.6% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...
Shares of Zai Lab Limited Unsponsored ADR (ZLAB) have gained 1.4% over the past four weeks to close the last trading session at $26.84, but there could still be a solid upside left in the stock if ...
This page features the latest news about the Zai Lab stock. Zai Lab Limited Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 Zai Lab (NASDAQ:ZLAB) Limited (ZLAB; HKEX: 9688 ...
21d
GlobalData on MSNFDA grants ODD status to Zai Lab’s lung cancer treatmentThe US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), ZL-1310, for small cell lung cancer (SCLC).
We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against ...
SHANGHAI & CAMBRIDGE, Mass., January 23, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results